About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Infection and Immunity in pediatric patients research group is a multidisciplinary pediatric research group made up of health professionals involved in translational research in the field of pediatric infectious diseases and immunodeficiencies, two related fields in terms of pathophysiology and clinical implications. It is a consolidated research group recognized by the AGAUR and is the only one with the accreditation of the Jeffrey Modell Foundation in research in the field of primary immunodeficiencies throughout the state.
The group was officially created in 2010, belongs to the area of Infectious Diseases and participates in the transversal programs of Advanced Translational Immunology and Rare Diseases and actively participates in national and international competitive projects, carries out multiple academic and industry-linked clinical trials and has increased the number and quality in recent years. In addition, it has its own laboratory specially dedicated to advanced immune studies.
PMID: 37939154 Journal: PLoS Neglected Tropical Diseases Year: 2023 Reference: PLoS Negl Trop Dis. 2023 Nov 8;17(11):e0011751. doi: 10.1371/journal.pntd.0011751. Impact factor: Publication type: Paper in international publication Authors: Aixut, Sandra; Bargues, Ma Dolores; Bocanegra, Cristina; Espiau, Maria; Fernandez-Polo, Aurora; Martinez-Camprecios, Joan; Mas-Coma, Santiago; Molina, Israel; Mossalilo, Patricia; Nindia, Arlette et al. DOI: 10.1371/journal.pntd.0011751
PMID: 37935260 Journal: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY Year: 2023 Reference: J Allergy Clin Immunol. 2023 Nov 5:S0091-6749(23)01390-8. doi: 10.1016/j.jaci.2023.10.018. Impact factor: Publication type: Paper in international publication Authors: Albert, Michael H; Andersson, Tommy; Aumann, Volker; Bakhtiar, Shahrzad; Barlogis, Vincent; Booth, Claire; Buddingh, Emmeline P; Cagdas, Deniz; Castelle, Martin; Chan, Alice Y et al. DOI: 10.1016/j.jaci.2023.10.018
PMID: 37942255 Journal: Frontiers in Public Health Year: 2023 Reference: Front Public Health. 2023 Oct 24;11:1265323. doi: 10.3389/fpubh.2023.1265323. eCollection 2023. Impact factor: Publication type: Paper in international publication Authors: Aixut, Sandra; Bargues, Ma Dolores; Bocanegra, Cristina; de Pando, Thais; Elvira, David; Espiau, Maria; Gay, Daniel; Martinez-Camprecios, Joan; Mas-Coma, Santiago; Molina, Israel et al. DOI: 10.3389/fpubh.2023.1265323
PMID: 37942955 Journal: Transplant Infectious Disease Year: 2023 Reference: Transpl Infect Dis. 2023 Nov 9:e14183. doi: 10.1111/tid.14183. Impact factor: Publication type: Paper in international publication Authors: Albert, Michael H; Aumann, Volker; Bakhtiar, Shahrzad; Barlogis, Vincent; Booth, Claire; Buddingh, Emmeline P; Cagdas, Deniz; Castelle, Martin; Chan, Alice Y; Chandrakasan, Shanmuganathan et al. DOI: 10.1111/tid.14183
The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.
The study, which is part of the European RECOMB project, is currently recruiting volunteers.
This clinical trial is part of the European project RBDCOV, led by HIPRA in which Vall d'Hebron participates, whose recruitment is still open.
